Skip to main content
Erschienen in: Calcified Tissue International 6/2007

01.12.2007

Three Novel Mutations of the PHEX Gene in Three Chinese Families with X-linked Dominant Hypophosphatemic Rickets

verfasst von: Weibo Xia, Xunwu Meng, Yan Jiang, Mei Li, Xiaoping Xing, Li Pang, Ou Wang, Yu Pei, Li-Yun Yu, Yue Sun, Yingying Hu, Xueying Zhou

Erschienen in: Calcified Tissue International | Ausgabe 6/2007

Einloggen, um Zugang zu erhalten

Abstract

X-linked dominant hypophosphatemia (XLH, OMIM307800), the most prevalent form of inherited rickets in humans, is a dominant disorder of phosphate homeostasis characterized by growth retardation, rachitic and osteomalacic bone disease, hypophosphatemia, and renal phosphate wasting. The gene responsible for XLH was identified by positional cloning and designated PHEX (formerly PEX) to depict a phosphate-regulating gene homologous with endopeptidases on the X chromosome. Recently, extensive mutation analysis of the PHEX gene has revealed a wide variety of gene defects in XLH. The ethnic distribution of the mutations is very widespread but only a few mutations in Chinese have been reported. To analyze the molecular basis in three unrelated Chinese families with XLH, we determined the nucleotide sequence of the PHEX gene and fibroblast growth factor 23 (FGF23) gene of affected members. The serum FGF23 concentrations of these patients with XLH were also measured. Three different novel mutations were observed in these three families: one deletion mutation c.264delG causing p.W88 X; one missense mutation c.1673C>G causing p.P558A; one nonsense mutation c.1809G>A causing p.W603 X. Serum concentration of FGF23 in XLH patients of these three families was significantly higher than normal. The results suggest that PHEX gene mutations were responsible for XLH in these patients and these mutations may contribute to a higher serum FGF23 level.
Literatur
1.
Zurück zum Zitat Rasmussen H, Tenenhouse HS (1995) Mendelian hypophosphatemias. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The Metabolic and Molecular Basis of Inherited Disease, vol 2. McGraw Hill, New York, pp 3717–3745 Rasmussen H, Tenenhouse HS (1995) Mendelian hypophosphatemias. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The Metabolic and Molecular Basis of Inherited Disease, vol 2. McGraw Hill, New York, pp 3717–3745
2.
Zurück zum Zitat Whyte MP, Schranck FW, Armamento R (1996) X-linked hypophosphataemia: a search for gender, race, anticipation, or parent of origin effects on disease expression in children. J Clin Endocrinol Metab 81:4075–4080PubMedCrossRef Whyte MP, Schranck FW, Armamento R (1996) X-linked hypophosphataemia: a search for gender, race, anticipation, or parent of origin effects on disease expression in children. J Clin Endocrinol Metab 81:4075–4080PubMedCrossRef
3.
Zurück zum Zitat Econs MJ, McEnery PT (1997) Autosomal dominant hypophosphataemic rickets/osteomalacia: Clinical characterization of a novel renal phosphate wasting disorders. J Clin Endocrinol Metab 82:674–681PubMedCrossRef Econs MJ, McEnery PT (1997) Autosomal dominant hypophosphataemic rickets/osteomalacia: Clinical characterization of a novel renal phosphate wasting disorders. J Clin Endocrinol Metab 82:674–681PubMedCrossRef
4.
Zurück zum Zitat Rowe PS (1994) Molecular biology of hypophosphataemic rickets and oncogenic osteomalacia. Hum Genet 94:457–467PubMedCrossRef Rowe PS (1994) Molecular biology of hypophosphataemic rickets and oncogenic osteomalacia. Hum Genet 94:457–467PubMedCrossRef
5.
Zurück zum Zitat HYP Consortium (1995) A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 11:130–136 HYP Consortium (1995) A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 11:130–136
6.
Zurück zum Zitat Rowe PS, Goulding JN, Francis F, Oudet C, Econs MJ, Hanauer A, Lehrach H, Read AP, Mountford RC, Summerfield T, Weissenbach J, Fraser W, Drezner MK, Davies KE, O’Riordan JL (1996) The gene for X-linked hypophosphataemic rickets maps to a 200–300 kb region in Xp22.1, and is located on a single YAC containing a putative vitamin D response element (VDRE). Hum Genet 97:345–352PubMed Rowe PS, Goulding JN, Francis F, Oudet C, Econs MJ, Hanauer A, Lehrach H, Read AP, Mountford RC, Summerfield T, Weissenbach J, Fraser W, Drezner MK, Davies KE, O’Riordan JL (1996) The gene for X-linked hypophosphataemic rickets maps to a 200–300 kb region in Xp22.1, and is located on a single YAC containing a putative vitamin D response element (VDRE). Hum Genet 97:345–352PubMed
7.
Zurück zum Zitat Holm IA, Huang X, Kunkel LM (1997) Mutational analysis of the PEX gene in patients with X-linked hypophosphatemic rickets. Am J Hum Genet 60:790–797PubMed Holm IA, Huang X, Kunkel LM (1997) Mutational analysis of the PEX gene in patients with X-linked hypophosphatemic rickets. Am J Hum Genet 60:790–797PubMed
8.
Zurück zum Zitat Du L, Desbarats M, Viel J, Glorieux FH, Cawthorn C, Ecarot B (1996) cDNA cloning of the murine Pex gene implicated in X-linked hypophosphatemia and evidence for expression in bone. Genomics 36:22–28PubMedCrossRef Du L, Desbarats M, Viel J, Glorieux FH, Cawthorn C, Ecarot B (1996) cDNA cloning of the murine Pex gene implicated in X-linked hypophosphatemia and evidence for expression in bone. Genomics 36:22–28PubMedCrossRef
9.
Zurück zum Zitat Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656-1663PubMedCrossRef Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656-1663PubMedCrossRef
10.
Zurück zum Zitat Weber T, Liu S, Indridason O, Quarles LD (2003) Serum FGF23 levels in normal and disordered phosphorus homeostasis. J. Bone Miner Res 18:1227–1234PubMedCrossRef Weber T, Liu S, Indridason O, Quarles LD (2003) Serum FGF23 levels in normal and disordered phosphorus homeostasis. J. Bone Miner Res 18:1227–1234PubMedCrossRef
11.
Zurück zum Zitat Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, Kumar R, Schiavi SC (2001) FGF23 inhibits renal tubular phosphate transport and is a phex substrate. Biochem Biophys Res Commun 284(4):977-981PubMedCrossRef Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, Kumar R, Schiavi SC (2001) FGF23 inhibits renal tubular phosphate transport and is a phex substrate. Biochem Biophys Res Commun 284(4):977-981PubMedCrossRef
12.
Zurück zum Zitat Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD (2003) Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278:37419–37426PubMedCrossRef Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD (2003) Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278:37419–37426PubMedCrossRef
13.
Zurück zum Zitat Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD (2006) Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 291:E38–E49PubMedCrossRef Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD (2006) Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 291:E38–E49PubMedCrossRef
14.
Zurück zum Zitat Rowe PS, Oudet CL, Francis F, Sinding C, Pannetier S, Econs MJ, Strom TM, Meitinger T, Garabedian M, David A, Macher MA, Questiaux E, Popowska E, Pronicka E, Read AP, Mokrzycki A, Glorieux FH, Drezner MK, Hanauer A, Lehrach H, Goulding JN, O’Riordan JL (1997) Distribution of mutations in the PEX gene in families with X-linked hypophosphataemic rickets (HYP). Hum Mol Genet 6:539–549PubMedCrossRef Rowe PS, Oudet CL, Francis F, Sinding C, Pannetier S, Econs MJ, Strom TM, Meitinger T, Garabedian M, David A, Macher MA, Questiaux E, Popowska E, Pronicka E, Read AP, Mokrzycki A, Glorieux FH, Drezner MK, Hanauer A, Lehrach H, Goulding JN, O’Riordan JL (1997) Distribution of mutations in the PEX gene in families with X-linked hypophosphataemic rickets (HYP). Hum Mol Genet 6:539–549PubMedCrossRef
15.
Zurück zum Zitat Jan de Beur SM, Levine MA (2002) Molecular pathogenesis of hypophosphatemic rickets. J Clin Endocrinol Metab 87:2467–2473CrossRef Jan de Beur SM, Levine MA (2002) Molecular pathogenesis of hypophosphatemic rickets. J Clin Endocrinol Metab 87:2467–2473CrossRef
16.
Zurück zum Zitat Cho HY, Lee BH, Kang JH, Ha IS, Cheong HI, Choi Y (2005) A clinical and molecular genetic study of hypophosphatemic rickets in children. Pediatr Res 58:329–333PubMedCrossRef Cho HY, Lee BH, Kang JH, Ha IS, Cheong HI, Choi Y (2005) A clinical and molecular genetic study of hypophosphatemic rickets in children. Pediatr Res 58:329–333PubMedCrossRef
17.
Zurück zum Zitat Cho HY, Lee BH, Kang JH, Ha IS, Cheong HI, Choi Y (1998) A PHEX gene mutation is responsible for adult-onset vitamin d-resistant hypophosphatemic osteomalacia: evidence that the disorder is not a distinct entity from x-linked hypophosphatemic rickets. J Clin Endocrinol Metab. 83:3459–3462CrossRef Cho HY, Lee BH, Kang JH, Ha IS, Cheong HI, Choi Y (1998) A PHEX gene mutation is responsible for adult-onset vitamin d-resistant hypophosphatemic osteomalacia: evidence that the disorder is not a distinct entity from x-linked hypophosphatemic rickets. J Clin Endocrinol Metab. 83:3459–3462CrossRef
18.
Zurück zum Zitat Holm IA, Nelson AE, Robinson BG, Mason RS, Marsh DJ, Cowell CT, Carpenter TO (2001) Mutational analysis and genotype-phenotype correlation of the phex gene in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 86:3889-3899PubMedCrossRef Holm IA, Nelson AE, Robinson BG, Mason RS, Marsh DJ, Cowell CT, Carpenter TO (2001) Mutational analysis and genotype-phenotype correlation of the phex gene in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 86:3889-3899PubMedCrossRef
19.
Zurück zum Zitat Francis F, Strom TM, Hennig S, Boddrich A, Lorenz B, Brandau O, Mohnike KL, Cagnoli M, Steffens C, Klages S, Borzym K, Pohl T, Oudet C, Econs MJ, Rowe PS, Reinhardt R, Meitinger T, Lehrach H (1997) Genomic organization of the human PEX gene mutated in X-linked dominant hypophosphatemic rickets. Genome Res 7:573–585PubMed Francis F, Strom TM, Hennig S, Boddrich A, Lorenz B, Brandau O, Mohnike KL, Cagnoli M, Steffens C, Klages S, Borzym K, Pohl T, Oudet C, Econs MJ, Rowe PS, Reinhardt R, Meitinger T, Lehrach H (1997) Genomic organization of the human PEX gene mutated in X-linked dominant hypophosphatemic rickets. Genome Res 7:573–585PubMed
20.
Zurück zum Zitat Walton RJ, Bijvoet OL (1975) Nomogram for derivation of renal threshold phosphate concentration. Lancet 2(7929):309–310PubMedCrossRef Walton RJ, Bijvoet OL (1975) Nomogram for derivation of renal threshold phosphate concentration. Lancet 2(7929):309–310PubMedCrossRef
21.
Zurück zum Zitat Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, Kassem M, Rackoff P, Zimering M, Dalkin A, Drobny E, Colussi G, Shaker JL, Hoogendoorn EH, Hui SL, Econs MJ (2006) Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 91:2055–2061PubMedCrossRef Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, Kassem M, Rackoff P, Zimering M, Dalkin A, Drobny E, Colussi G, Shaker JL, Hoogendoorn EH, Hui SL, Econs MJ (2006) Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 91:2055–2061PubMedCrossRef
22.
Zurück zum Zitat Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S. (2002) Increased circulatory level of biologically active full-length FGF23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957–4960PubMedCrossRef Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S. (2002) Increased circulatory level of biologically active full-length FGF23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957–4960PubMedCrossRef
23.
Zurück zum Zitat Lo FS, Kuo MT, Wang CJ, Chang CH, Lee ZL, Van YH (2006). Two novel PHEX mutations in Taiwanese patients with X-linked hypophosphatemic rickets. Nephron Physiol 103:157-163CrossRef Lo FS, Kuo MT, Wang CJ, Chang CH, Lee ZL, Van YH (2006). Two novel PHEX mutations in Taiwanese patients with X-linked hypophosphatemic rickets. Nephron Physiol 103:157-163CrossRef
24.
Zurück zum Zitat Tyynismaa H, Kaitila I, Nanto-Salonen K, Ala-Houhala M, Alitalo T (2000) Identification of fifteen novel PHEX gene mutations in Finnish patients with hypophosphatemic rickets. Hum Mutat 15:383-384PubMedCrossRef Tyynismaa H, Kaitila I, Nanto-Salonen K, Ala-Houhala M, Alitalo T (2000) Identification of fifteen novel PHEX gene mutations in Finnish patients with hypophosphatemic rickets. Hum Mutat 15:383-384PubMedCrossRef
25.
Zurück zum Zitat Sabbagh Y, Boileau G, DesGroseillers L, Tenenhouse HS (2001) Disease-causing missense mutations in the PHEX gene interfere with membrane targeting of the recombinant protein. Hum Mol Genet 10:1539–1546PubMedCrossRef Sabbagh Y, Boileau G, DesGroseillers L, Tenenhouse HS (2001) Disease-causing missense mutations in the PHEX gene interfere with membrane targeting of the recombinant protein. Hum Mol Genet 10:1539–1546PubMedCrossRef
26.
Zurück zum Zitat Sabbagh Y, Boileau G, Campos M, Carmona AK, Tenenhouse HS (2003) Structure and function of disease-causing missense mutations in the PHEX gene. J Clin Endocrinol Metab 88:2213-2222PubMedCrossRef Sabbagh Y, Boileau G, Campos M, Carmona AK, Tenenhouse HS (2003) Structure and function of disease-causing missense mutations in the PHEX gene. J Clin Endocrinol Metab 88:2213-2222PubMedCrossRef
27.
Zurück zum Zitat Tenenhouse HS (1999) X-linked phypophosphataemia: a homologous disorder in humans and mice. Nephrol Dial Transplant 14:333-341PubMedCrossRef Tenenhouse HS (1999) X-linked phypophosphataemia: a homologous disorder in humans and mice. Nephrol Dial Transplant 14:333-341PubMedCrossRef
28.
Zurück zum Zitat Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500–6505PubMedCrossRef Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500–6505PubMedCrossRef
29.
Zurück zum Zitat Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Juppner H, Jonsson KB (2004) Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145:3087–3094PubMedCrossRef Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Juppner H, Jonsson KB (2004) Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145:3087–3094PubMedCrossRef
30.
Zurück zum Zitat Bai X, Miao D, Li J, Goltzman D, Karaplis AC (2004) Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 145:5269–5279PubMedCrossRef Bai X, Miao D, Li J, Goltzman D, Karaplis AC (2004) Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 145:5269–5279PubMedCrossRef
31.
Zurück zum Zitat Saito H, Kusano K, Kinosaki M, Ito H, Hirata M, Segawa H, Miyamoto KI, Fukushima N (2003) Human fibroblast growth factor−23 mutants suppress Na-dependent phosphate co-transport activity and 1,25-dihydroxyvitamin D3 production. J Biol Chem 278:2206–2211PubMedCrossRef Saito H, Kusano K, Kinosaki M, Ito H, Hirata M, Segawa H, Miyamoto KI, Fukushima N (2003) Human fibroblast growth factor−23 mutants suppress Na-dependent phosphate co-transport activity and 1,25-dihydroxyvitamin D3 production. J Biol Chem 278:2206–2211PubMedCrossRef
Metadaten
Titel
Three Novel Mutations of the PHEX Gene in Three Chinese Families with X-linked Dominant Hypophosphatemic Rickets
verfasst von
Weibo Xia
Xunwu Meng
Yan Jiang
Mei Li
Xiaoping Xing
Li Pang
Ou Wang
Yu Pei
Li-Yun Yu
Yue Sun
Yingying Hu
Xueying Zhou
Publikationsdatum
01.12.2007
Verlag
Springer-Verlag
Erschienen in
Calcified Tissue International / Ausgabe 6/2007
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-007-9067-4

Weitere Artikel der Ausgabe 6/2007

Calcified Tissue International 6/2007 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.